HarmoniaMentisHarmoniaMentis

Mechanism of action

  1. Home
  2. UK HCP
  3. Discover ONTOZRY®▼ (cenobamate)

  4. You are here: Mechanism of action

Article

This promotional website is managed and funded by Angelini Pharma and is intended for UK and Ireland healthcare professionals only.

How does ONTOZRY®▼ (cenobamate) work?

ONTOZRY®: A dual mechanism of action

ONTOZRY® is thought to prevent seizure initiation and reduce seizure propagation through its action on two elements of the neurological signalling pathways involved in epilepsy. The precise mechanism of action by which ONTOZRY® exercises its therapeutic effects in patients with focal-onset seizures is unknown.1-6

ONTOZRY® has a dual, complementary mechanism of action which is thought to contribute to its antiseizure activity and clinical efficacy in adult patients with drug-resistant focal onset epilepsy.6

ASM=anti-seizure medication; Cl=chloride; GABA=gamma-aminobutyric acid; GABAA=gamma-amino butyric acid type A; Na=sodium.

Indications

United Kingdom: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti–epileptic medicinal products.1

Republic of Ireland: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti–epileptic medicinal products.1

1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.
2. Löscher W, et al. Epilepsia. 2021 Mar;62(3):596-614.
3. Schmidt D, Schachter SC. BMJ. 2014;348:g254.
4. Nakamura M, et al. Eur J Pharmacol. 2019;855:175-82.
5. Sharma R, et al. Eur J Pharmacol. 2020;879:173117.
6. Guignet M, et al. Epilepsia. 2020 Nov;61(11):2329-2339.

MAT-UKI-0246-P | September 2025